Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 4, 2005, Pages 863-867

  Williamson, Douglas S ^a   Parratt, Martin J ^a   Bower, Justin F ^a   Moore, Jonathan D ^a   Richardson, Christine M ^a   Dokurno, Pawel ^a   Cansfield, Andrew D ^a   Francis, Geraint L ^a   Hebdon, Richard J ^a   Howes, Rob ^a   Jackson, Philip S ^a   Lockie, Andrea M ^a   Murray, James B ^a   Nunns, Claire L ^a   Powles, Jenifer ^a   Robertson, Alan ^a   Surgenor, Allan E ^a   Torrance, Christopher J ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

CDK2; Cyclin dependent kinase; Pyrazolo 1,5 a pyrimidine

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PYRIMIDINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG;

ARTICLE; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN STRUCTURE;

EID: 20144386767     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.12.073     Document Type: Article

References (21)

1. A.W. Murray Cell 116 2004 221 234
2. J. Méndez Cell 114 2003 398 399
3. M. Pagano, and P.K. Jackson Cell 118 2004 535 538
4. T.G. Davies, D.J. Pratt, J.A. Endicott, L.N. Johnson, and M.E.M. Noble Pharmacol. Ther. 93 2002 125 133
5. S. Zhai, A.M. Senderowicz, E.A. Sausville, and W.D. Figg Ann. Pharmacother. 36 2002 905 911
6. L. Meijer, and E. Raymond Acc. Chem. Res. 36 2003 417 425
7. R.N. Misra, H.-y. Xiao, K.S. Kim, S. Lu, W.-C. Han, S.A. Barbosa, J.T. Hunt, D.B. Rawlins, W. Shan, S.Z. Ahmed, L. Qian, B.-C. Chen, R. Zhao, M.S. Bednarz, K.A. Kellar, J.G. Mulheron, R. Batorsky, U. Roongta, A. Kamath, P. Marathe, S.A. Ranadive, J.S. Sack, J.S. Tokarski, N.P. Pavletich, F.Y.F. Lee, K.R. Webster, and S.D. Kimball J. Med. Chem. 47 2004 1719 1728
8. In-house data
9. A.V. Kamath, S. Chong, M. Chang, and P.H. Marathe Cancer Chemother. Pharmacol. 55 2005 110 116
10. M. Pacek, T.A. Prokhorova, and J.C. Walter Cell Cycle 3 2004 401 403
11. All kinases from Upstate Ltd.; http://www.upstate.com.
12. Kinase assays were adapted from the following generic protocol, with ATP concentrations stated in the footnotes to Table 1 M.E. Lane, B. Yu, A. Rice, K.E. Lipson, C. Liang, L. Sun, C. Tang, G. McMahon, R.G. Pestell, and S. Wadler Cancer Res. 61 2001 6170 6177
13. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107 1112
14. 50 is the inhibitor concentration which reduced tumour cell growth by 50% over 72 h
15. T.G. Davies, J. Bentley, C.E. Arris, F.T. Boyle, N.J. Curtin, J.A. Endicott, A.E. Gibson, B.T. Golding, R.J. Griffin, I.R. Hardcastle, P. Jewsbury, L.N. Johnson, V. Mesguiche, D.R. Newell, M.E.M. Noble, J.A. Tucker, L. Wang, and H.J. Whitfield Nat. Struct. Biol. 9 2002 745 749
16. M.K. Dreyer, D.R. Borcherding, J.A. Dumont, N.P. Peet, J.T. Tsay, P.S. Wright, A.J. Bitonti, J. Shen, and S.-H. Kim J. Med. Chem. 44 2001 524 530
17. T. Novinson, B. Bhooshan, T. Okabe, G.R. Revankar, R.K. Robins, K. Senga, and H.R. Wilson J. Med. Chem. 19 1976 512 516
18. The PDB entry codes are 1Y8Y (CDK2/8a) and 1Y91 (CDK2/9a) H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne Nucleic Acids Res. 28 2000 235 242
19. J. Rosenblatt, H. De Bondt, J. Jancarik, D.O. Morgan, and S.-H. Kim J. Mol. Biol. 230 1993 1317 1319
20. A.C. Pierce, K.L. Sandretto, and G.W. Bemis Proteins 49 2002 567 576
21. Trova, M. P. PCT Int. Appl. WO 03/022805, 2003; Chem. Abstr. 2003, 221651